The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

• Ngā kaituhi matua: Jennifer Soung (Author), Vivian Laquer (Author), Joseph F. Merola (Author), Angela Moore (Author), Hany Elmaraghy (Author), Chaoran Hu (Author), Maria Lucia Buziqui Piruzeli (Author), Evangeline Pierce (Author), Esther Garcia Gil (Author), Abel D. Jarell (Author)
• Hōputu: Pukapuka
• I whakaputaina: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Introduction Lebrikizumab, a high-affinity IgG4 monoclonal antibody that selectively inhibits interleukin-13 with high binding affinity and slow dissociation rate, prevents the formation of the interleukin-4Rα/interleukin-13Rα1 heterodimer receptor signaling complex. Here we report the impa...